New Horizon’s Sales Surge as China Promotes Early Cancer Detection
Company’s first-mover advantage in at-home colorectal screening and China’s focus on early detection have turbocharged sales, though valuation remains frothy Key takeaways: New Horizon’s first-half revenues jumped more than fourfold,…
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
